JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37
Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc.
Immunovant Inc. (IMVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 9,500,000 | $152,000,000 | 4.87% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,457,881 | $87,326,096 | 0.85% | |
| 3. | Armistice Capital Steven Boyd | 5,200,000 | $83,200,000 | +16% | 1.44% |
| 4. | Point72 Asset Management Steve Cohen | 3,336,250 | $53,379,994 | +317% | 0.1% |
| 5. | Two Seas Capital Sina Toussi | 2,252,772 | $36,044,352 | +38% | 0.61% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing | |
| $5.81 | 20,000 | $116,200.00 | 393,358 | 2022-09-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.30 | 1,272 | $20,733.60 | 220,553 | 2025-10-08 | Filing | |
| $16.30 | 1,585 | $25,835.50 | 203,334 | 2025-10-08 | Filing | |
| $18.15 | 2,805 | $50,910.75 | 204,919 | 2025-07-23 | Filing | |
| $18.15 | 2,385 | $43,287.75 | 221,825 | 2025-07-23 | Filing | |
| $17.24 | 1,160 | $19,998.40 | 224,210 | 2025-07-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 205,219 | $3,308,130 | 0% | |
| 2. | 12,651 | $203,934 | 0% | |
| 3. | 2,502 | $40,332 | 0% | |
| 4. | 437 | $7,044 | 0% | |
| 5. | 350 | $5,642 | 0% |
News See All
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Where is Immunovant (IMVT) Heading According to Analysts?
Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Smart Money Ratings For 20 Most Undervalued Stocks
We have passed a quarter into 2025, and the U.S. economy sends mixed signals, causing investors to scramble and decode them. The U.S.
11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
10 Best Low Cost Stocks to Buy According to Billionaires
Markets are wobbling, and panic is becoming the headline. At times when stocks are tumbling, headlines are filled with forecasts that cause anxiety for investors. But it's not new.
Hedge Fund Resource Center Billionaire Hedge Funds
